Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line atezolizumab + tiragolumab plus paclitaxel + cisplatin versus placebo plus paclitaxel + cisplatin in advanced esophageal squamous cell carcinoma
CTR20201863Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tiragolumab, atezolizumab, paclitaxel, cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Roche. Started Dec 2020; status: completed.
02
Drugs
tiragolumabatezolizumabpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20201863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201863.